Navigation Links
New company announcement: TERGUS PHARMA
Date:6/12/2012

RESEARCH TRIANGLE PARK, N.C., June 12, 2012 /PRNewswire-iReach/ -- In response to company growth and expansion of topical pharmaceutical product development services, Analytical Solutions, Inc. (ASI) is pleased to announce today that it is changing its name to Tergus Pharma, LLC, to better echo the company's new growth trajectory.

Tergus Co-Founder and CEO, Dr. Vijendra NALAMOTHU, most recently Head of Dermatology R&D for Promius Pharma and Dr. Reddy's Laboratories, brings 18 years of topical drug product development and commercialization experience to Tergus clients. Since 1994, Tergus Co-Founder and President, Dr. Kailas Thakker, has been providing quality analytical services to the pharmaceutical industry with an emphasis on In Vitro Release Testing (IVRT), functional testing for semisolids and topical products.

Tergus (Latin for "skin") is now providing dermatology drug development services from concept to commercialization.  With the acquisition of new equipment and strategic additions to the scientific team, Tergus Pharma is pleased to announce that it is now servicing its clients with a broader range of topical drug development services, including product development strategy & design; target product profile development; formulation development; analytical method development & validation; preclinical & clinical supplies manufacturing; program management & logistics leadership; scale-up & technology transfer oversight; regulatory CMC consulting; disease model development; clinical development strategy; and development plan creation to ensure fastest path to in vivo or clinical proof of concept studies.

Tergus' core expertise will remain focused in topical dosage forms, including creams, ointments, lotions, liquids, suspensions, gels, hydrogels, pastes, pump sprays, topical aerosols, foams, microencapsulation, liposomes, suppositories and nail lacquers.

Think Topicals. Think Tergus

About Tergus Pharma

Tergus Pharma, LLC is a privately held dermatology-focused organization offering complete pharmaceutical product development services. Tergus' GMP/GLP compliant, state of the art laboratories are located in Research Triangle Park, North Carolina. For additional information please visit www.TergusPharma.com 

Media Contact: Ms. Kathy Meserve, Tergus Pharma, +1(919) 549-9700 Ext.105, KMeserve@TergusPharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Tergus Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company To Present At The William Blair Growth Stock Conference
2. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
3. Masimo to Present at William Blair & Company 32nd Annual Growth Stock Conference
4. K-V Pharmaceutical Company States That Its Policy is Not to Comment on Unusual Market Activity
5. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
6. Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series
7. Judge Upholds $3.3 Million Judgment In Favor of Fox Insurance Company Against Former Pharmacy Benefit Manager
8. Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference
9. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
10. The Female Health Company Reports Second Quarter Operating Results
11. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , ... partnership with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South ... care plan incentives to a patient’s remote health progress, empowering the patient to take ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be ... conditions and has helped many women become pregnant upon treating their diagnosis. ... and simple outpatient evaluations. We can provide the necessary information to diagnose ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more about ... ) that demonstrates how this advanced plant breeding technology is a more efficient ... fewer resources. It highlights the business’ principles, research and collaboration efforts in this ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... is proud to announce that it has received 510(k) clearance from the U.S. ... Home and the MyoCycle Pro. , Both devices are stationary cycling systems that ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
Breaking Medicine News(10 mins):